Briacell Therapeutics Corp.
BCTXBriaCell Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care by harnessing the body's immune system.
Table of contents
Earnings
Next report
Date not yet announcedCompetitors
By market cap
By revenue growth
Profile
BriaCell Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care by harnessing the body's immune system. The company's core value proposition centers on its proprietary whole-cell immunotherapy platform, which is designed to activate the immune system against cancer cells, particularly in patients with advanced metastatic breast cancer who have failed prior lines of therapy.
BriaCell is a clinical-stage developer with a Fast Track designated lead candidate in Phase 3 trials, competing against major pharmaceutical firms in the high-growth cancer immunotherapy market.
Questions, answered.
- What is Briacell Therapeutics Corp.'s market cap?
- Briacell Therapeutics Corp. (BCTX) has a market capitalization of $30.9M and trades on NASDAQ.
- Who are Briacell Therapeutics Corp.'s competitors?
- Briacell Therapeutics Corp.'s key competitors include Marker Therapeutics, Inc., Bristol-Myers Squibb, Gilead Sciences, and others. These companies compete in similar markets and product categories.
- Who does Briacell Therapeutics Corp. partner with?
- Briacell Therapeutics Corp.'s notable partners include Incyte, Merck & Co., BeiGene, and others.
- What subsidiaries does Briacell Therapeutics Corp. have?
- Briacell Therapeutics Corp.'s subsidiaries include BriaPro Therapeutics Corp..
- Where is Briacell Therapeutics Corp. headquartered?
- Briacell Therapeutics Corp. is headquartered in Canada and employs approximately 12 people. It has been publicly traded since 2023.